UPDATE: Qiagen Q2 Revenues Bounce 9 Percent; Plans to Buy Back $100M in Shares | GenomeWeb

The story has been updated to include comments from Qiagen's conference call.

NEW YORK (GenomeWeb News) – Qiagen reported after the close of the market on Tuesday that revenues increased 9 percent year over year as both instruments and consumables and related sales bounced in the double digits.

The company also announced its first share buyback program with plans to repurchase up to $100 million in Qiagen shares.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.